US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Vera Therapeutics, Inc. - Class A Common Stock
(NQ:
VERA
)
30.42
-0.57 (-1.84%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vera Therapeutics, Inc. - Class A Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
November 11, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
October 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
October 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
↗
October 28, 2024
Vera Therapeutics announces ORIGIN Phase 2b trial data on atacicept, showing sustained IgAN improvement and kidney function stability over 96 weeks.
Via
Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
↗
October 28, 2024
Via
Benzinga
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
↗
October 28, 2024
The company is working on a treatment for IgA nephropathy, a condition that affects how well the kidneys work.
Via
Investor's Business Daily
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 26, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
October 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
October 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
September 16, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
September 12, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
↗
September 03, 2024
Via
Benzinga
Vera Therapeutics to Participate at September Investor Conferences
August 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Vera Therapeutics
Via
GlobeNewswire
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
↗
August 08, 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
July 01, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
June 11, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
↗
June 03, 2024
Via
Benzinga
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
↗
May 31, 2024
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs.
Via
Benzinga
Topics
Economy
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
↗
May 29, 2024
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.
Via
Benzinga
Topics
Artificial Intelligence
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
May 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
May 25, 2024
From
Vera Therapeutics
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
